Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Suspicious

<< Previous

Bullboard Posts

Next >>

Comment by Charly50on May 11, 2022 5:50pm

181 Views

Post# 34675751

RE:RE:RE:RE:RE:RE:RE:Suspicious

Piotr Witkowski

rospom1a4Mu3uig01: fi. 083

 						Remember Liz?
 						Liz struggled with diabetes most of her life. Eventually also her kidneys gave up and she needed dialysis. Instead, she received a living donor kidney transplant 5 years ago. 
 						However afterwards, her blood glucose control was even more challenging and her HbA1c increased above 10. 

 						Exactly a year ago, Liz received a single islet transplant and now she celebrates her first year living off insulin with HbA1c of 5.5!
 						Also her dogs, Whitley and Reuben are happier than ever.

 						For patients like Liz who need to take daily immunosuppression medication to protect their kidney transplant anyway, islet transplantation brings the pure benefit of an insulin free life. 

 						There are many patients with T1DM in the US, who have received kidney, heart or lung transplants and could have enjoyed life without insulin after islet transplantation just like Liz. 

 						Unfortunately, islet transplantation is still not broadly available to patients with diabetes in the US, despite it's being approved and reimbursable procedure in Canada, Australia, Japan and several Europeans countries. 

In those countries, islets are regulated as any other organ/tissue for transplantation. By contrast, the FDA regulates islets as drugs, compromising patient safety and creating bureaucratic barrier for the approval of islet transplantation as a standard of care in the US. Unfortunately, our call for the regulatory update remains unanswered (www.isletsforus.org 								 
).

bersetzung anzeigen